Traws Pharma, Inc.
TRAWDrugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Feb 15, 2026
7dMarket Overview
Stock performance and market intelligence
2 upcoming, 1 past
Ratutrelvir (83-0060) non-randomised Phase 2 Results Expected
Primary completion for Ratutrelvir (83-0060) non-randomised trial (NCT07157007) in COVID - 19
SourceTRX-100 Phase 2 Results Expected
Primary completion for TRX-100 trial (NCT07371650) in Influenza
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
rigosertib sodium
Myelodysplastic Syndromes
ON 01910.Na
Myelodysplastic Syndrome
Gemcitabine
Metastatic Pancreatic Adenocarcinoma
rigosertib
Head and Neck Squamous Cell Carcinoma
Narazaciclib
Endometrioid Endometrial Cancer
Oral rigosertib
Myelodysplastic Syndromes
TRX-100
Influenza
Ratutrelvir (83-0060) non-randomised
COVID - 19
Azacitidine
Myelodysplastic Syndrome
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
rigosertib sodium | Phase 3 | Myelodysplastic Syndromes | - |
ON 01910.Na | Phase 3 | Myelodysplastic Syndrome | - |
Gemcitabine | Phase 3 | Metastatic Pancreatic Adenocarcinoma | - |
rigosertib | Phase 2 | Head and Neck Squamous Cell Carcinoma | - |
Narazaciclib | Phase 2 | Endometrioid Endometrial Cancer | - |
Oral rigosertib | Phase 2 | Myelodysplastic Syndromes | - |
TRX-100 | Phase 2 | Influenza | - |
Ratutrelvir (83-0060) non-randomised | Phase 2 | COVID - 19 | - |
Azacitidine | Phase 2 | Myelodysplastic Syndrome | - |
Regulatory & News
Approvals, filings, and latest developments